CAR-T therapies – media

Karyopharm Seeks FDA Approval for Selinexor Drug for Multiple Myeloma

The Newton Massachusetts-based company, Karyopharm Therapeutics, who developed a new class of drugs to treat multiple myeloma, is in the process of submitting a new drug application to the FDA for their selinexor drug.
- Source: MedCityNews
- 419
- July 24, 2018
cancer CAR-T therapies FDA New Approvals
Carisma Therapeutics Bags $53 Million in Series A Funding led by AbbVie

Philadelphia-based Carisma Therapeutics bagged $53 million in series A funding, led by AbbVie Ventures Co-led by HealthCap, new backers Wellington Partners, MRL Ventures Fund, TPG Biotech, and Agent Capital.
- Source: FierceBiotech
- 737
- June 28, 2018
biotech CAR-T therapies Company Insights funding
Autolus Raises Impressive $150 Million for T-cell Therapy

The IPO has provided the biotech major with the financial bandwidth to aggressively pursue its new generation of CAR-T variants on a broader level, with the advancement of several therapies or the start of clinical trials over the next couple of months.
- Source: FierceBiotech
- 598
- June 25, 2018
acquisition cancer CAR-T therapies Company Insight
Cellectis Snags $164 Million in IPO to Advance CAR-T Programs

Today the company has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering. The funding will be used to continue the development of Cellectis’ off-the-shelf CAR-T products and drive them toward regulatory approval.
- Source: biospace
- 680
- April 13, 2018
CAR-T therapies Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.